Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib vs Imatinib in Newly Diagnosed Ph+ CML-CP
NCT01511289Phase 3Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Aug 2011
- Primary completion
- Feb 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of radotinib in chronic myeloid leukemia (CML) (3 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoint: Major Molecular Response at 12 months. Started Aug 2011; status: completed.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01511289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511289.